Painreform Ltd Cash Flow Conversion Efficiency
Painreform Ltd cash flow conversion efficiency. Based on the latest financial reports, Painreform Ltd (PRFX) has a cash flow conversion efficiency ratio of -0.117x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-991.00K) by net assets ($8.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PRFX company net worth for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Painreform Ltd (2017–2024)
Cash flow conversion efficiency of Painreform Ltd from 2017 to 2024. This chart illustrates how Painreform Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Painreform Ltd for real-time trading data and today's change.
Painreform Ltd Cash Flow Conversion Ratio Explained
Painreform Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Painreform Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Painreform Ltd ranked by their cash flow conversion efficiency. Review PRFX financial flexibility score to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Savannah Resources Plc
LSE:SAV
|
-0.033x |
|
KARELIAN DIA.R. EO-00025
F:KJY1
|
N/A |
|
Bohra Industries Limited
NSE:BOHRAIND
|
0.009x |
|
SRx Health Solutions Inc.
NYSE MKT:SRXH
|
18.676x |
|
ESS Tech Inc
NYSE:GWH
|
-1.425x |
|
Univa Foods Limited
NSE:UNIVAFOODS
|
-0.001x |
|
Spectur Ltd
AU:SP3
|
-0.224x |
|
Sienna Resources Inc
V:SIE
|
-0.071x |
Annual Cash Flow Conversion Efficiency for Painreform Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Painreform Ltd from 2017 to 2024. Also see Painreform Ltd (PRFX) total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.82 Million | $-12.62 Million | -6.919x | -649.96% |
| 2023-12-31 | $7.24 Million | $-6.68 Million | -0.923x | -57.43% |
| 2022-12-31 | $11.02 Million | $-6.46 Million | -0.586x | -61.72% |
| 2021-12-31 | $18.08 Million | $-6.55 Million | -0.362x | -135.56% |
| 2020-12-31 | $16.62 Million | $-2.56 Million | -0.154x | -242.03% |
| 2019-12-31 | $-5.62 Million | $-609.00K | 0.108x | -23.97% |
| 2018-12-31 | $-4.46 Million | $-635.00K | 0.142x | -40.57% |
| 2017-12-31 | $-3.63 Million | $-870.00K | 0.240x | -- |
About Painreform Ltd
PRF Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinica… Read more